Q-omics provides the consensus-scored ZC3H8 profile across patient tissues and cancer cell-line models. ZC3H8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZC3H8 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ZC3H8 protein abundance shows 24,147 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where ZC3H8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H8 survival associations across molecular data types. ZC3H8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H8 RNA expression–survival associations across cancer types. High ZC3H8 expression shows unfavorable associations in KIRP, ACC, KICH, UCEC and KIRC, but favorable associations in BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ZC3H8 RNA expression.
This table summarizes ZC3H8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H8 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, LIHC, LUAD and HNSC. The THCA box plot shows higher ZC3H8 RNA expression in normal versus tumor tissue (log2 FC = −0.824, t-test p < 0.001).
This table shows molecular features associated with ZC3H8 in patient tissues and cancer cell lines. In patient samples, ZC3H8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
